Drug firm Glenmark Pharmaceuticals on Monday said it has cut price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19, by 27 per cent to ₹75 per tablet.
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of ₹103 per tablet.
In a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is ₹75 per tab, it said.
"The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country," the filing said.
"Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country," Glenmark Pharmaceuticals Senior Vice President and Head – India business Alok Malik said.
Further, the company has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study, the filing added.
"We expect this post marketing surveillance study to shed more light on the drug's clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu," Malik added.
On June 20, Glenmark announced that it received manufacturing and marketing approval from India's drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.
Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India. The trial results will be available shortly, the company said.
Glenmark is also conducting another phase 3 clinical trial to evaluate the efficacy of two antivirals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult COVID-19 patients in India.
Shares of Glenmark Pharma were trading 1.34 per cent lower at ₹421.00 apiece on BSE. PTI SVK DRR DRR
Jun 4, 2020 0 1478
Jun 7, 2020 0 991
Jul 16, 2020 2 8243
Jun 11, 2020 0 1519
Jun 24, 2020 0 1120
Jun 1, 2020 1 4069
Nov 22, 2019 0 2111
Two of the petrol offerings in the car include a 1.2-litre Kappa dual VTVT engine...
Aug 26, 2019 0 2014
The Coralarium, is located at the Fairmont Maldives Sirru Fen Fushi resort.
Aug 27, 2021 0 434
Setu has already created a beta version for the application programming interface.
Sep 26, 2021 1 1597
October month is jam-packed with several vacations and festivities, and many banks...
Sep 14, 2021 0 471
State Bank of India (SBI) has further said that if they fail to do so, they will...
Aug 30, 2019 0 1287
Renault is offering the Triber in four variants with the RXE variant kicking things...
Jun 15, 2020 0 1861
Dry shampoo can be a life-saviour but the ones in the market are full of chemicals....
Aug 27, 2021 0 526
Xiaomi India has announced ‘Mi Flagship Days’, bringing this year’s best prices...
Sep 2, 2019 0 2041
Tata Motors reported a 58 per cent decline in its domestic passenger vehicle sales...
Apr 16, 2020 0 1515
Since, Coronavirus (COVID-19) has spread around the whole world and caused a pandemic....
Sep 14, 2021 0 471
Sep 14, 2021 0 389
Sep 14, 2021 0 198
Sep 1, 2021 0 12803
Jun 2, 2020 0 112
Sep 14, 2021 0 10
Sep 14, 2021 0 9
Aug 9, 2021 2 8
Dec 20, 2020 0 7